Wird geladen...
A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge
Post-marketing reporting of adverse drug events is essential for new medications, as pre-FDA approval studies lack sufficient subject numbers to detect signals for rare events. Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equaled or excee...
Gespeichert in:
| Veröffentlicht in: | J Clin Med Res |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elmer Press
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5916542/ https://ncbi.nlm.nih.gov/pubmed/29707095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr3394w |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|